Discovery of the first nonpeptide agonist of the GPR14/Urotensin-II receptor: 3-(4-Chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one (AC-7954)

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 4950-4953

  Croston, Glenn E ^a   Olsson, Roger ^a   Currier, Erika A ^a   Burstein, Ethan S ^a   Weiner, David ^a   Nash, Norman ^a   Severance, Daniel ^a   Allenmark, Stig G ^b   Thunberg, Linda ^b   Ma, Jian Nong ^a   Mohell, Nina ^a   O'Dowd, Brian ^c   Brann, Mark R ^a,d   Hacksell, Uli ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYL) 3 [2 (DIMETHYLAMINO)ETHYL]ISOCHROMAN 1 ONE; AC 7954; G PROTEIN COUPLED RECEPTOR; ISOCHROMAN DERIVATIVE; NEUROPEPTIDE; UNCLASSIFIED DRUG; UROTENSIN II;

ARTICLE; BIOAVAILABILITY; CARDIOVASCULAR RESPONSE; CHEMICAL ANALYSIS; CYCLIZATION; DRUG TARGETING; ENANTIOMER; MOLECULAR CLONING; PEPTIDE ANALYSIS; RECEPTOR UPREGULATION; TARGET CELL;

EID: 0037038316     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm025551+     Document Type: Article

References (20)

1. Marchese, A.; Heiber, M.; Nguyen, T.; Heng, H. H.; Saldivia, V. R.; Cheng, R.; Murphy, P. M.; Tsui, L. C.; Shi, X.; Gregor, P.; et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 1995, 29, 335-344.
2. Totsune, K.; Kakanashi, K.; Arihara, Z.; Sone, M.; Satoh, F.; Ito, S.; Kimura, Y.; Sasano, H.; Murakami, O. Role of urotensin II in patients on dialysis. Lancet 2001, 358, 810-811.
3. Ames, R. S.; Sarau, H. M.; Chambers, J. K.; Willette, R. N.; Aiyar, N. V.; Romanic, A. M.; Louden, C. S.; Foley, J. J.; Sauermelch, C. F.; Coatney, R. W.; Ao, Z.; Disa, J.; Holmes, S. D.; Stadel, J. M.; Martin, J. D.; Liu, W. S.; Glover, G. I.; Wilson, S.; McNulty, D. E.; Ellis, C. E.; Elshourbagy, N. A.; Shabon, U.; Trill, J. J.; Hay, D. W.; Ohlstein, E. H.; Bergsma, D. J.; Douglas, S. A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401, 282-286.
4. Liu, Q.; Pong, S. S.; Zeng, Z.; Zhang, Q.; Howard, A. D.; Williams, D. L., Jr.; Davidoff, M.; Wang, R.; Austin, C. P.; McDonald, T. P.; Bai, C.; George, S. R.; Evans, J. F.; Caskey, C. T. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun. 1999, 266, 174-178.
5. Douglas, S. A.; Ohlstein, E. H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med. 2000, 10, 229-237.
6. Mori, M.; Sugo, T.; Abe, M.; Shimomura, Y.; Kurihara, M.; Kitada, C.; Kikuchi, K.; Shintani, Y.; Kurokawa, T.; Onda, H.; Nishimura, O.; Fujino, M. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun. 1999, 265, 123-129.
7. Nothacker, H. P.; Wang, Z.; McNeill, AM.; Saito, Y.; Merten, S.; O'Dowd, B.; Duckles, S. P.; Civelli, O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat. Cell. Biol. 1999, 1, 383-385.
8. Messier, T. L.; Dorman, C. M.; Brauner-Osborne, H.; Eubanks, D.; Brann, M. R. High throughput assays of cloned adrenergic, muscarinic, neurokinin, and neurotrophin receptors in living mammalian cells. Pharmacol. Toxicol. 1995, 76, 308-311.
9. Weiner, D. M.; Burstein, E. S.; Nash, N.; Croston, G. E.; Currier, E. A.; Vanover, K. E.; Harvey, S. C.; Donohue, E.; Hansen, H. C.; Andersson, C. M.; Spalding, T. A.; Gibson, D. F.; Krebs-Thomson, K.; Powell, S. B.; Geyer, M. A.; Hacksell, U.; Brann, M. R. 5-Hydroxytryptamine 2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 2001, 299, 268-276.
10. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3-26.
11. Vaulx, R. N.; Puterbaugh, W. H.; Hauser, C. R. Metalation of N-methyl-o-toluamine with excess n-butyllithium. Condensations with ketones and aldehydes. Cyclizations. J. Org. Chem. 1964, 29, 3514-3517.
12. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
13. de Tullio, P.; Delarge, J.; Pirotte, B. Therapeutic and chemical developments of cholecystokinin receptor ligands. Expert Opin. Investig. Drugs 2000, 9, 129-146.
14. Ueno, A.; Naraba, H.; Kojima, F.; Morita, E.; Oh-ishi, S. FR190997, a novel bradykinin B2 agonist, expresses longer action than bradykinin in paw edema formation and hypotensive response. Immunopharmacology 1999, 45, 89-93.
15. Perlman, S.; Schambye, H. T.; Rivero, R. A.; Greenlee, W. J.; Hjorth, S. A.; Schwartz, T. W. Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor. J. Biol. Chem. 1995, 270, 1493-1496.
16. Rohrer, S. P.; Birzin, E. T.; Mosley, R. T.; Berk, S. C.; Hutchins, S. M.; Shen, D. M.; Xiong, Y.; Hayes, E. C.; Parmar, R. M.; Foor, F.; Mitra, S. W.; Degrado, S. J.; Shu, M.; Klopp, J. M.; Cai, S. J.; Blake, A.; Chan, W. W.; Pasternak, A.; Yang, L.; Patchett, A. A.; Smith, R. G.; Chapman, K. T.; Schaeffer, J. M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282, 737-740.
17. For a discussion about ectopic binding, see: Spalding, T. A., Trotter, C.; Skjærbæk, N.; Messier, T. L.; Currier, E. A.; Burstein, E. S.; Li, D.; Hacksell, U.; Brann, M. R. Discovery of an ectopic activation site on the ml musacarinic receptor. Mol. Pharmacol. 2002, 61, 1297-1302.
18. Itoh, H.; Itoh, Y.; Rivier, J.; Lederis, K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am. J. Physiol. 1987, 252 (2 Pt 2), R361-R366.
19. Bhaskaran, R.; Arunkumar, A. I.; Yu C. NMR and dynamical simulated annealing studies on the solution conformation of urotensin II. Biochim. Biophys. Acta 1994, 1199, 115-122.
20. Structures related to 1 have been patented for compounds that elicited hypotension, hypertension, or diuresis. A U. S. patent involving related compounds from Houlihan, W. J, and Nadelson, J. in 1975 (US 3880885) relates diuretic and antihypertensive activity. The biological responses observed with these compounds may have been related to modulation of the UII receptor. Hence, the present study suggests a molecular mechanism for these earlier pharmacological observations.